23-04-2025 23:00 via medpagetoday.com

Novel DPP-1 Drug Trims Exacerbation Risk in Bronchiectasis

(MedPage Today) -- Targeting airway inflammation with investigational brensocatib reduced exacerbations with bronchiectasis, the ASPEN trial showed.
The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations...
Read more »

Medical Industry news



Tumor-Infiltrating Clonal Hematopoiesis Increased Risk of Poor Outcomes in Cancer
Young-Onset Dementia Risk Rises With Metabolic Syndrome
Lorundrostat Lowered BP in Uncontrolled, Treatment-Resistant Hypertension
Antiviral Reduced Transmission of Influenza to Close Contacts
Groups Decry Loss of Funding for 'Critically Important' GI Disease Network
No Extra Cancer Recurrence Risk Seen for RA Patients on Biologic Therapy
Antibiotic Candidate for Lyme Disease Boosts Hope for Custom Approach
BTK Inhibitors for Follicular Lymphoma
What Physicians Can Learn From Pope Francis
Coldplay Singer's Depression; Add-On Cobenfy Flopped; Uptick in Psilocybin Use
Novavax Says Its COVID Shot Is on Track for Full FDA Approval After Delay
Anti-Vaxxers Say Bioweapon Caused Measles Outbreak; DOGE Holds Health Grants Hostage
High Response Rate in Myeloma With Novel CAR-T After Anti-BCMA Failure
Bill Treats mRNA Vaccines as 'Weapons'; Brain Drain Begins? New Ice Bucket Challenge
Desktop versie